Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Udonitrectag - MimeTech

Next Previous
Drug Profile

Udonitrectag - MimeTech

Alternative Names: MT-8; Negermin lysine salt; REC 0/0559; REC-0559

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Universita degli Studi di Firenze
  • Developer MimeTech; Recordati
  • Class Anti-inflammatories; Antianaemics; Antiglaucomas; Cardiovascular therapies; Eye disorder therapies; Nerve growth factors; Neuroprotectants; Skin disorder therapies
  • Mechanism of Action Apoptosis inhibitors; Autophagy inhibitors; Nerve growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transplant rejection; Keratitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Keratitis
  • Phase I/II Diabetic foot ulcer
  • Preclinical Choroideraemia; Reperfusion injury; Skin disorders; Varicose ulcer
  • No development reported Dry eyes; Glaucoma; Myocardial infarction; Pressure ulcer; Retinitis pigmentosa; Sickle cell anaemia; Transplant rejection

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for preclinical development in Dry-eyes in Italy
  • 28 Mar 2025 No recent reports of development identified for preclinical development in Glaucoma in Italy
  • 28 Mar 2025 No recent reports of development identified for preclinical development in Myocardial-infarction in Italy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top